MHRA Exclusive: A Spotlight on Regulation in RNAi Therapies

John Johnston, Clinical Assessor, Biologicals and Biotechnology Unit, to Provide a Keynote Address at RNA Therapeutics 2017

London, United Kingdom, January 06, 2017 --( SMi Group are delighted to welcome expertise from the MHRA in a keynote presented by industry expert John Johnston, at the 8th annual RNA Therapeutics show when it returns to Central London next February. With a focus on overcoming common governing pitfalls, the address will provide attendees with informed guidance and exclusive updates on MHRA regulation.

John Johnston is respected in the industry for his expertise in clinical and metabolic medicine and often writes about European pharmaceutical regulation. His most recent publications include articles on highly personalised medicines and custom-made anti-sense oligonucleotide medicinal products. With almost a decade's worth of experience in the role, John is currently working as a clinical assessor at the Medicines & Healthcare products Regulatory Agency (MHRA).

As well as providing an overview in current legislation, his presentation will offer essential guidelines on reporting clinical data and best practice on interacting with regulators.

The established event set to take place on 22nd & 23rd February will aim to deliver a scientific toolkit of ideas to implement targeted delivery and will feature, not only the latest scientific research, but also a selection of hand-picked industry case studies from those driving medical progress.

John Johnston will be joining other notable speakers in the field at RNA Therapeutics 2017 including:

Bo Rode Hansen, Director, Technology and Partnered Discovery, Roche
Jeffrey Ulmer, Head Preclinical Research and Development, GSK Vaccines US
Sanyogitta Puri, Associate Principal Scientist, AstraZeneca
Nagy Habib, Head of Surgery, Co-Founder, Imperial College Healthcare NHS Trust, MiNA Therapeutics
Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech RNA Pharmaceuticals
Nicole Meisner-Kober, Senior Investigator, RNA Biology, Novartis Institutes for Biomedical Research
David Giljohann, CEO, Exicure
Shai Erlich, Chief Medical Officer & President USA, Quark Pharmaceuticals
Amotz Shemi, CEO, Silenseed

Further information is available at

8th Annual Event: RNA Therapeutics 2017
Conference: 22nd & 23rd Feb | Interactive workshop: 21st Feb
Copthorne Tara Hotel, Kensington, London, UK

Contact Information:
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email:

To register for the conference, visit or contact Fateja Begum on Tel: +44 (0)20 7827 6184 / Email:

To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email:

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at
SMi Group
Teri Arri
+44 (0) 20 7827 6162